Richard Whitley to Clinical Trials, Phase I as Topic
This is a "connection" page, showing publications Richard Whitley has written about Clinical Trials, Phase I as Topic.
Connection Strength
0.090
-
Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors. Hum Gene Ther. 2020 10; 31(19-20):1132-1139.
Score: 0.039
-
Evaluation of new anti-infective drugs for the treatment of viral encephalitis. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov; 15 Suppl 1:S195-9.
Score: 0.023
-
Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications. Clin Microbiol Infect. 2002 Sep; 8(9):551-63.
Score: 0.011
-
Evaluation of new anti-infective drugs for the treatment of acute bacterial meningitis. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov; 15 Suppl 1:S182-8.
Score: 0.006
-
Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov; 15 Suppl 1:S189-94.
Score: 0.006
-
Evaluation of new anti-infective drugs for the treatment of toxoplasma encephalitis. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov; 15 Suppl 1:S200-5.
Score: 0.006